A short update on new approaches to celiac disease

Main Article Content

Btihaj Al Ibrahmi
Abdellatif Bour

Keywords

Celiac Disease; Gluten-free diet; Elafin ; Endoproteolytic enzyme; Pseudocereals.

Abstract

Celiac disease is an autoimmune enteropathy of the small intestine, related to gluten intolerance occurring in genetically predisposed patients. Currently, the only available treatment is a lifelong gluten-free diet. However, the total avoidance of gluten is difficult and poses a challenge to patients, nutritionists and treating physicians. For this reason, scientists have developed in recent years new therapeutic approaches complementary to dietary treatment, such as modification of gluten to make gliadin non-toxic, reduction of the inflammatory response with elafin and Lactococcus Lactis, degradation of gluten by endoproteolytic enzymes, and correction of nutritional deficiencies by adding pseudo-cereals to the diet of celiac patients. This literature review focuses on the different treatment strategies for celiac disease previously studied and summarizes the latest advances in this field.

Abstract 481 | PDF Downloads 388

References

1. Montalto M, Curigliano V, Santoro L, et al. Management and treatment of lactose malabsorption. WJG 2006; 12: 187.
2. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterology Journal 2019; 7:583-613.
3. Dubé C, RostomA, Cranney A, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: A systematic review. Gastroenterology 2005; 128: S57-S67.
4. Catassi C, Ratsch I M, Gandolfi, L, et al. Why is coeliac disease endemic in the people of the Sahara? The Lancet 1999; 354: 647-648.
5. Tkoub E M. Maladie cœliaque de l’adulte. Revue française d'allergologie et d'immunologie clinique 2008 ; 48 : S27-S31.
6. Roma E, Panayiotou J, Karantana H, et al. Changing pattern in the clinical presentation of pediatric celiac disease: A 30-year study. Digestion 2009; 80: 185-191.
7. Cosnes J, Nion-Larmurier I. Les complications de la maladie cœliaque. Pathologie Biologie 2013 ; 61 : e21-e26.
8. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123: 1428-1435.
9. Smedby KE, Åkerman M, Hildebrand H, et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005; 54: 54-59.
10. Rostom A, Murray JA, Kagnoff M F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 1981-2002.
11. HAS. Recherche d’anticorps dans la maladie cœliaque : diagnostic et suivi de l’observance du régime sans gluten, 2007. http://www.has-sante.fr.
12. Matuchansky C, Rousseau S, Morin MC. Maladie cœliaque de l’adulte : actualités du régime sans gluten. Cahiers de Nutrition et de Diététique 2004; 39: 311-317.
13. Boukezoula F, Zidoune MNE. Observance du régime sans gluten et ses conséquences sur l’état nutritionnel et la santé chez 100 malades cœliaques à Tébassa , Algérie. Médecine des maladies métaboliques 2014; 8: 440-444.
14. Crowe SE. Celiac disease, pp 123-148, In: Nutrition and gastrointestinal d’immunologie clinique 2008; 48: 27-31.
15. Erroux J. Blé. Encyclopédie berbère ; 1991.p. 1526-1536.
16. Boudreau A, Ménard G, eds. Le Blé : éléments fondamentaux et transformation. Presses Université Laval, 1992.
17. Marsh M N. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology1992; 102: 330-354.
18. Gomez JC, Selvaggio GS, Viola M, et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. The American journal of gastroenterology 2001; 96: 2700-2704.
19. Parada A, Araya M, Pérez-Bravo Fet al. Amerindian mtDNA haplogroups and celiac disease risk HLA haplotypes in mixed-blood Latin American patients. Journal of pediatric gastroenterology and nutrition 2011; 53: 429-434.
20. Idir KA. « Épidémiologie de la maladie cœliaque dans le monde » Epidemiology of Celiac Disease worldwide." Med Sci 7 2020: 1-5.
21. Akobeng AK, Thomas AG. Systematic review: tolerable amount of gluten for people with coeliac disease. Alimentary pharmacology & therapeutics 2008; 27: 1044-1052.
22. Rashid M, Cranney A, Zarkadas M,et al . Celiac disease: evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics 2005; 116: e754-e759.
23. Becissel L, Ben Feriah M, Gheddar NEI, Zouaghi MF. Enquête épidémiologique sur la maladie coeliaque dans la wilaya de Jijel. Diss, Université de Jijel, 2020.
24. Rubio T, Alberto, Joseph A. Murray. Classification and management of refractory coeliac disease. Gut 2010; 59:547-557.
25. Mariani P, Viti MG, Montouri M et al. The gluten-free diet: a nutritional risk factor for adolescents with celiac disease?. Journal of pediatric gastroenterology and nutrition 1998; 27: 519-523.
26. Farnetti S, Zocco MA, Garcovich M, Gasbarrini A , Capristo E. Functional and metabolic disorders in celiac disease: new implications for nutritional treatment. Journal of medicinal food 2014; 17: 1159-1164.
27. Valletta E. Fornaro M, Cipolli M, Conte S, Bissolo F, Danchielli C. Celiac disease and obesity: need for nutritional follow-up after diagnosis. European journal of clinical nutrition 2010; 64: 1371-1372.
28. Miranda J, Lasa A, Bustamante MA, Churruca I, Simon E. Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten. Plant foods for human nutrition 2014; 69: 182-187.
29. Ferrara P, Cicala M, Tiberi E, et al. High fat consumption in children with celiac disease. Acta Gastro-Enterologica Belgica 2009; 72: 296-300.
30. Theethira TG, Dennis M. Celiac disease and the gluten-free diet: consequences and recommendations for improvement. Digestive Diseases 2015; 33: 175-182.
31. Agarwal A, Singh A, Mehtab W et al. Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver. Intestinal research 2021; 19: 106.
32. Aziz I, Imran, Evans et al. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis 2011; 20: 27-31.
33. Wieser H, Koehler, P. The biochemical basis of celiac disease. Cereal Chemistry 2008; 85: 1-13.
34. Altenbach SB, Allen PV. Transformation of the US bread whe wheat ‘Butte 86’and silencing of omega-5 gliadin genes. GM crops 2011; 2: 66-73.
35. Schmid M, Fellermann K, Fritz P, Wiedow O, Stange EF, Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn’s disease. Journal of leukocyte biology 2007; 81: 907-915.
36. Motta JP, Bermúdez-Humarán LG, Deraison C, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Science translational medicine 2012; 4:158ra144-158ra144.
37. Steinert PM, Marekov LN. The Proteins Elafin, Filaggrin, Keratin Intermediate Filaments, Loricrin, and Small Proline-rich Proteins 1 and 2 Are Isodipeptide Cross-linked Components of the Human Epidermal Cornified Cell Envelope (∗). Journal of Biological Chemistry 1995; 270: 17702-17711.
38. Galipeau HJ, Wiepje M, Motta JP, et al.Une protéine naturelle, l’Elafine contre l’intolérance au gluten?, Communiqué de presse Inserm. American Journal of Gastroenterology, 2014.https://presse.inserm.fr/une-proteine-naturelle-lelafine-contrelintolerance-au-gluten/12104/.
39. Vanhoof G, Goossens F, Hendriks L, et al. Cloning and sequence analysis of the gene encoding human lymphocyte prolyl endopeptidase. Gene 1994; 149: 363-366.
40. Matysiak–Budnik T, Candalh C, Cellier C, et al. Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology 2005; 129: 786-796.
41. Pyle GG, Paaso B, Anderson BE, et al .Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clinical Gastroenterology and Hepatology 2005; 3: 687-694.
42. Tye-Din JA, Anderson RP, Ffrench RA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clinical immunology 2010; 134: 289-295.
43. Yoosuf, Shakira, Govind K, et al. Treatment of gluten-related disorders. Gluten-Related Disorders. Academic Press 2022. 149-182.
44. Lahdeaho M, Maki M, Kaukinen K, et al. ALV003, a novel glutenase, attenuates gluten-induced small intestinal mucosal injury in celiac disease patients: a randomized controlled phase 2A clinical trial. Gut 2011; 60.
45. Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Digestive diseases and sciences 2012; 57: 440-450.
46. Martínez-Villaluenga C, Peñas E, Hernández-Ledesma B. Pseudocereal grains: Nutritional value, health benefits and current applications for the development of gluten-free foods. Food and Chemical Toxicology 2020; 137: 111178.
47. Comino I, Real A, Barro, F, et al. The gluten-free diet: testing alternative cereals tolerated by celiac patients. Nutrients 2013; 5: 4250-4268.
48. Alvarez-Jubete L, Arendt EK, Gallagher E. Nutritive value of pseudocereals and their increasing use as functional gluten-free ingredients. Trends in Food Science & Technology 2010; 21: 106-113.
49. Anubhuti S. Amaranth: A Pseudocereal. Nutri Food Sci Int J.2017; 3: 555611.
50. FAO. Quinoa: An ancient crop to contribute to world food security. Regional Office for Latin America and the Caribbean 2011; 60.
51. 51. James LEA. Quinoa (Chenopodium quinoa Willd.): composition, chemistry, nutritional, and functional properties. Advances in food and nutrition research 2009; 58: 1-31.
52. Zevallos VF, Herencia IL, Chang F, Donnelly S, Ellis JH , Ciclitira PJ .Gastrointestinal Effects of Eating Quinoa (Chenopodium quinoaWilld.) in Celiac Patients. Official journal of the American College of Gastroenterology| ACG 2014; 109: 270-278.
53. Schilperoord P. Plantes cultivées en Suisse-La fève commune des champs. 2017
54. Steadman KJ, Burgoon MS, Lewis BA, Edwardson SE,Obendorf RL. Buckwheat seed milling fractions: description, macronutrient composition and dietary fibre. Journal of Cereal Science 2001; 33: 271-278.
55. Mazza G, Oomah BD. Buckwheat as a food and feed. Specialty grains for food and feed 2005: 375-293.
56. Li SQ, Zhang QH. Advances in the development of functional foods from buckwheat. Critical reviews in food science and nutrition 2001; 41: 451-464.
57. Dinu M, Macchia D, Pagliai G, et al. Symptomatic efficacy of buckwheat products in Non-Celiac Gluten Sensitivity (NCGS). Asia Pacific Journal of Clinical Nutrition 2017; 26: 630-636.
58. Teutonico RA, Knorr D. Amaranth: composition, properties, and applications of a rediscovered food crop. Food technology 1985; 39: 49-61.
59. Early D, Early JC. Tranferencia de tecnologıa indıgena para la preparación de la Kiwicha (Amaranthus). Primeira parte. El amaranto y su potencial. Boletın 1987; 4 : 8-12.
60. Berger A, Gremaud G, Baumgartner M, et al. Cholesterol-lowering properties of amaranth grain and oil in hamsters. International journal for vitamin and nutrition research 2003; 73: 39-47.
61. Singhal RS, Kulkarni PR. Amaranths–an underutilized resource 1998; 125-139.
62. Thompson T. Case problem: questions regarding the acceptability of buckwheat, amaranth, quinoa, and oats from a patient with celiac disease. Journal of the American Dietetic Association 2001; 101: 586-586.